This increase in exosomal PD-L1 during PD1-inhibitor treatment may be an adaptive response of tumor cells to T-cell regeneration through interferon-gamma production by reinvigorated CD8+ T cells [32]. This evidence concerns the gene IFNG and neoplasm.